Sebastian Arrizabalaga | Medicine and Health Sciences | Innovative Research Award

Published on by Top Teachers

Innovative Research Award

Sebastian Arrizabalaga — Oregon Health & Science University, United States

Sebastian Arrizabalaga
Affiliation Oregon Health & Science University
Country United States
Scopus ID 58650782300
Documents 3
Citations 128
h-index 2
Subject Area Ophthalmology
Event Top Teachers Awards
ORCID 0009-0007-5387-3007

Sebastian Arrizabalaga is a researcher affiliated with Oregon Health & Science University whose work encompasses experimental ophthalmology, retinal disease research, neural stem cell formulations, preclinical models, and quantitative assessment of retinal neuroprotection. His research experience combines laboratory experimentation, animal-based studies, imaging, data analysis, and research project management, supporting translational investigations relevant to retinal disorders and emerging therapeutic strategies. [1][2]

Abstract

Sebastian Arrizabalaga’s academic profile is centered on ophthalmic and retinal research conducted at Oregon Health & Science University. His research activities include evaluating neural stem cell approaches, studying retinal neuroprotection in animal models, and contributing to preclinical investigations involving retinal therapeutics. His technical background includes spectroscopy, chromatography, fluorescence imaging, confocal microscopy, fundus imaging, electroretinography, ocular procedures, and quantitative data analysis. Published work demonstrates participation in studies addressing retinal degeneration, geographic atrophy, and experimental therapeutic development. [1][3][4][5]

Keywords

Ophthalmology; retinal research; neural stem cells; retinal neuroprotection; geographic atrophy; age-related macular degeneration; preclinical research; retinal imaging; electroretinography; animal models; translational medicine; cell-based therapy.

Introduction

Sebastian Arrizabalaga’s research trajectory connects biochemical laboratory training with experimental ophthalmology. After completing a Bachelor of Arts in Chemistry at Reed College, including a thesis examining the functionality of the bacterial tellurium resistance protein TerB, he developed broader expertise in laboratory science, animal experimentation, imaging, and retinal research. His subsequent work at Oregon Health & Science University has focused on experimental approaches relevant to retinal degeneration and therapeutic development. [2][4]

Research Profile

His current research profile includes project and experiment management, preparation of clinical trial approval documentation, laboratory administration, animal colony management, experimental design, and quantitative analysis. Technical competencies encompass UV/Vis spectroscopy, biochemistry, liquid chromatography–mass spectrometry, fluorescence spectroscopy, R programming, immunofluorescence staining, confocal microscopy, optokinetic tracking, fundus imaging, electroretinography, ocular injections and implants, cryosectioning, and microtome-based tissue preparation.[1][2]

  • Retinal and ophthalmic experimental research.
  • Neural stem cell and retinal neuroprotection studies.
  • Preclinical investigation of therapies for retinal degeneration.
  • Quantitative retinal imaging and functional assessment.
  • Laboratory, animal-model, and research-project management.

Research Contributions

A principal contribution of Arrizabalaga’s research record is the quantitative evaluation of retinal neuroprotection produced by distinct human neural stem cell formulations in the Royal College of Surgeons rat model. This work provides experimental evidence for comparing cell-based approaches within a retinal degeneration model and contributes to the broader development of regenerative strategies for retinal disease.[4]

His research also includes work on improving human neural stem cell formulations for potential application to geographic atrophy, a form of advanced dry age-related macular degeneration. In related preclinical research, his collaborative publication record intersects with investigations of retinal gene editing and cell-based therapeutic safety and efficacy, reflecting a translational research pathway from experimental formulation and biological evaluation toward potential clinical applications. [3][5]

Publications

Sebastian Arrizabalaga’s highly relevant publications include a 2023 study quantifying retinal neuroprotection from two human neural stem cell formulations in the RCS rat, followed by a 2024 study addressing improvements to human neural stem cell formulations for geographic atrophy treatment. His collaborative research record also includes work on retinal genome editing using lipid nanoparticles and preclinical studies of GMP-grade retinal pigment epithelial cells for dry age-related macular degeneration, placing his contributions within active translational ophthalmology research. [4][3][5]

  1. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468.
  2. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841.
  3. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535.
  4. Surendran, H., Soundararajan, L., Patlolla, N., Stoddard, J., Arrizabalaga, S., Liu, Z., Gopal, L., Su, X., Ryals, R. C., Battu, R., & Pal, R. (2024). IND-enabling preclinical safety and efficacy studies using GMP-grade human iPSC-derived retinal pigment epithelial cells for treating dry age-related macular degeneration. Investigative Ophthalmology & Visual Science, 65(7), 716.

Research Impact

The research record is relevant to contemporary ophthalmology because retinal degeneration and geographic atrophy require improved methods for protecting or replacing vulnerable retinal cells. Sebastian Arrizabalaga’s participation in studies involving neural stem cell formulations, retinal imaging, functional testing, and preclinical safety and efficacy contributes to the experimental evidence base used to evaluate candidate regenerative and translational therapies. The listed academic profile reports 128 citations across three documents, with an h-index of 2.[1]

Award Suitability

For the Innovative Research Award associated with the Top Teachers Awards, Sebastian Arrizabalaga presents a research profile characterized by laboratory-based ophthalmic investigation, multidisciplinary collaboration, quantitative experimentation, and translational relevance. His work on retinal neuroprotection and neural stem cell formulations provides a coherent research theme connecting experimental models with potential therapeutic development. The combination of technical laboratory expertise, animal-model research, imaging, and publication activity supports consideration within an innovation-focused academic recognition framework.[1][2]

Conclusion

Sebastian Arrizabalaga’s academic record reflects developing expertise in experimental ophthalmology, retinal degeneration research, neural stem cell approaches, and preclinical therapeutic evaluation. His publications and research responsibilities demonstrate engagement with collaborative translational studies addressing retinal neuroprotection and geographic atrophy. Together with a broad technical laboratory skill set and experience managing experimental research activities, these elements form a focused profile in contemporary retinal science. [1]

References

  1. Scopus author profile for Sebastian Arrizabalaga, author identifier 58650782300. https://www.scopus.com/pages/authors/58650782300
  2. ORCID record for Sebastian Arrizabalaga, ORCID 0009-0007-5387-3007. https://orcid.org/0009-0007-5387-3007
  3. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468. https://doi.org/10.1038/s41467-023-42189-3
  4. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841. https://iovs.arvojournals.org/article.aspx?articleid=2788186
  5. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535. https://iovs.arvojournals.org/article.aspx?articleid=2796734

Sebiha Demir | Health Sciences | Best Researcher Award

Published on by Top Teachers

Ms. Sebiha Demir | Health Sciences | Best Researcher Award

University Hospital Bonn | Germany

Ms. Sebiha Demir is a dedicated medical researcher specializing in neonatology, neonatal neuroprotection, and perinatal brain injury. Her research focuses on improving clinical outcomes for asphyxiated newborns through evidence-based innovations in therapeutic hypothermia and neurophysiological monitoring. She integrates advanced diagnostic tools such as amplitude-integrated electroencephalography (aEEG) and biochemical profiling to identify early predictors of hypoxic-ischemic encephalopathy (HIE), advancing precision medicine in neonatal intensive care. Her notable publication, “Abnormal Amplitude‐Integrated Electroencephalography and Acidosis as Key Criteria Initiating Therapeutic Hypothermia in Asphyxiated Newborns – Data From the German Hypothermia Registry” (Acta Paediatrica, 2025), demonstrates her significant contribution to establishing objective criteria for initiating life-saving interventions in high-risk neonates. Through collaborative research with multidisciplinary teams across Europe, Dr. Demir has enriched neonatal care protocols and contributed to shaping guidelines for early neurological assessment and treatment strategies. Her internationally recognized publications reflect a strong academic impact and translational value in pediatric and clinical neuroscience. With over 380 citations, an h-index of 10 on Scopus, and 12 on Google Scholar, her scholarly influence and commitment to impactful research are evident. As a forward-thinking clinician–scientist, she continues to advance neonatal research by integrating data-driven insights with compassionate care. Dr. Demir’s excellence, innovation, and dedication to improving neonatal health outcomes position her as a leading figure in her field and a deserving recipient of the Best Researcher Award, honoring her outstanding contributions to advancing neonatal medicine and inspiring future generations of medical scientists.

Publication Profile

Orcid

Featured Publications

Demir, S., Groteklaes, A., Dresbach, T., Müller, A., & Sabir, H. (2025, October 29). Abnormal amplitude-integrated electroencephalography and acidosis as key criteria initiating therapeutic hypothermia in asphyxiated newborns – Data from the German Hypothermia Registry. Acta Paediatrica.

Joan-Lluis Vives Corrons | Health Sciences | Outstanding Scientist Award

Published on by Top Teachers

Prof. Joan-Lluis Vives Corrons | Health Sciences | Outstanding Scientist Award

Academic Background

Prof. Joan-Lluis Vives-Corrons holds a Medical Doctor degree and is a specialist in Haematology from the University of Barcelona. He completed advanced training as a fellow at Hôpital Beaujon in Paris and as a visiting fellow at The Scripps Research Institute. He has served as a professor of Medicine at the University of Barcelona and has been deeply involved in education and mentorship in haematology throughout his career. According to Scopus and Google Scholar records, his work has been cited extensively, with over 1,467 documents citing his research, 81 documents authored, and an h-index of 21, reflecting his sustained influence in the field.

Research Focus

Prof. Joan-Lluis Vives Corrons research focuses on the study of rare and congenital anaemias, encompassing the molecular and genetic mechanisms underlying red blood cell disorders. He has a strong interest in the standardization of haematology laboratory practices and in improving diagnostic approaches for haemoglobinopathies and enzymopathies. His work bridges clinical practice and translational research to advance patient care for rare anaemias.

Work Experience

Prof. Joan-Lluis Vives Corrons has held leadership roles in haematology laboratories and clinical departments, serving as head of the Haematology Laboratory and Red Cell Pathology Units at the Hospital Clinic of the University of Barcelona. He has also led the Red Cell Pathology and Haematopoietic Disorders Research Group at the Josep Carreras Institute for Leukemia Research and currently oversees the Clinical Centre for Ambulatory Medicine in Barcelona. He has coordinated large-scale networks for the diagnosis and follow-up of rare haematological disorders, contributing significantly to public health programs such as newborn screening for sickle-cell disease.

Key Contributions

Prof. Joan-Lluis Vives Corrons has pioneered the development of diagnostic methods for rare anaemias, implemented quality assessment schemes in haematology, and contributed to the standardization of automated laboratory analyzers. His research has led to the discovery of multiple novel mutations in genes responsible for red blood cell disorders, enhancing the understanding of their molecular basis. He has facilitated international collaboration through European networks for rare anaemias and supported education and training programs for haematologists and laboratory professionals.

Awards & Recognition

Recognized for his exceptional research and leadership, Prof. Vives-Corrons has been honored with the Outstanding Scientist Award for his groundbreaking contributions to the study of rare anaemias. His work is widely acknowledged for advancing clinical and laboratory haematology practice while fostering global collaborations in rare disease research.

Professional Roles & Memberships

Prof. Joan-Lluis Vives Corrons has held significant professional roles, including Secretary General of the International Society of Haematology and representative membership in the European Union Committee of Experts in Rare Diseases. He is affiliated with multiple national and international scientific societies and serves on editorial boards of leading journals in haematology. His work with ORPHANET, EURORDIS, and various standardization organizations underscores his commitment to improving rare disease diagnostics and care.

Profile

Scopus | Orcid 

Featured Publications

Vives-Corrons, J. L., et al. (2024). SARS-CoV-2 infection and anemia—A focus on RBC deformability and membrane proteomics—Integrated observational prospective study. Microorganisms.

Vives-Corrons, J. L., et al. (2023). The pyruvate kinase deficiency global longitudinal (Peak) registry: Rationale and study design. BMJ Open.

Vives-Corrons, J. L., et al. (2022). Haemoglobin Bristol-Alesha in a child with non-spherocytic severe haemolytic anaemia and marked anisochromic poikilocytosis with basophilic stippling and amorphous intracellular content. Blood Cells, Molecules and Diseases.

Vives-Corrons, J. L., et al. (2022). Concomitant hereditary spherocytosis and pyruvate kinase deficiency in a Spanish family with chronic hemolytic anemia: Contribution of laser ektacytometry to clinical diagnosis. Cells.

Vives-Corrons, J. L., et al. (2022). Red cell ektacytometry in two patients with chronic hemolytic anemia and three new α-spectrin variants. Annals of Hematology.

Impact Statement / Vision

Prof. Joan-Lluis Vives Corrons to advance the understanding and management of rare anaemias through innovative research, international collaboration, and the integration of molecular diagnostics into clinical practice. His vision emphasizes improving patient outcomes while promoting education and quality standards in haematology worldwide.